David Raphael focuses his practice on complex antitrust litigation representing classes of direct purchasers of pharmaceutical products who allege that drug manufacturers have violated antitrust law through schemes to wrongfully impede or delay generic drug competition.
Mr. Raphael’s work on pharmaceutical antitrust cases has contributed to settlements on behalf of classes of direct purchasers totaling hundreds of millions of dollars, including King Drug Co. of Florence, Inc. v. Cephalon, Inc. (E.D.Pa.) and In re: Namenda Direct Purchaser Antitrust Litigation (S.D.N.Y), which are the largest settlements ever achieved in class action cases alleging impaired generic competition. Mr. Raphael and others on the legal team representing direct purchasers in these cases were honored by the American Antitrust Institute in 2019 and 2020 for “Outstanding Antitrust Litigation Achievement in Private Law Practice.” Mr. Raphael also has experience litigating class action cases involving RICO and government regulatory misconduct, including Abshire v. La. Dept.of Ins. (19th J.D.C., Louisiana), in which a multi-million dollar recovery was obtained for the class with Mr. Raphael serving as co-lead class counsel.
Mr. Raphael is a native of New Orleans. He received his undergraduate and law degrees from Louisiana State University (B.S. 1989; J.D. 1993). He is licensed to practice law in Louisiana, and has been admitted to practice in the United States Supreme Court; the United States Courts of Appeals for the Federal, Third and Fifth Circuits; and the United States District Courts for the Eastern, Middle and Western Districts of Louisiana.
Copyright © 2022 Smith, Segura, Raphael & Leger LLP - All Rights Reserved.
221 Ansley Blvd Alexandria LA 71303 318-445-4480